secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001867096-26-000020
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Jeffrey Sherman to retire from Xeris Biopharma board at 2026 annual meeting
--------------------------------------------------------------------------------

- Dr. Jeffrey Sherman notified Board of his retirement and will not stand for reelection at the 2026 Annual Meeting.
- Sherman will continue serving on Compensation and Nominating/Governance committees until his term expires.
- Board reduced from eight to seven directors effective after Sherman's term ends at the 2026 Annual Meeting.
- Sherman stated his retirement is not due to any disagreement with the company or its management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000020/0001867096-26-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000020/xers-20260420.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer